Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia
June 11 2018 - 8:30AM
Business Wire
– Recognized for Services to Medical
Research –
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that John
McHutchison, MD, Chief Scientific Officer and Head of Research and
Development, has been appointed an Officer of the Order of
Australia in recognition of his “distinguished service to medical
research in gastroenterology and hepatology, particularly through
the development of treatments for viral infections, and to the
biopharmaceutical industry.”
Dr. McHutchison is an internationally recognized leader in
gastroenterology and hepatology, with extensive expertise in
clinical and translational research in liver diseases. He joined
Gilead in 2010, and was appointed Chief Scientific Officer in March
2018. Under his leadership, Gilead has developed five medicines for
the treatment of chronic hepatitis B and hepatitis C that have been
used by nearly 2 million people around the world.
“I am deeply honored to receive this appointment,” said Dr.
McHutchison. “I have been fortunate to work with many gifted and
inspiring leaders in the liver disease field, and I am grateful to
them for many years of collaboration, support and friendship.”
The Order of Australia is awarded to Australian citizens and
other persons for achievement or meritorious service. An individual
who is appointed Officer is recognized for “distinguished service
of a high degree to Australia or to humanity at large.”
“John is an inquisitive and insightful scientist who has helped
to transform the outlook for millions of people with liver disease
around the world,” said John Milligan, PhD, Gilead’s President and
CEO. “We congratulate him on this prestigious recognition and look
forward to his continued leadership of our R&D programs.”
Dr. McHutchison has undergraduate degrees in medicine and
surgery from the University of Melbourne in Australia and completed
his residency in internal medicine and fellowship in
gastroenterology at the Royal Melbourne Hospital. He is a member of
the Royal Australasian College of Physicians.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties, and other factors. These
risks, uncertainties and other factors could cause actual results
to differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended March 31, 2018, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
For more information on Gilead Sciences,
please visit the company’s website at www.gilead.com, follow
Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180611005197/en/
Gilead Sciences, Inc.InvestorsSung Lee, 650-524-7792orMediaAmy
Flood, 650-522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024